PRAMEF1

Across TCGA pan-cancer cohorts, PRAMEF1 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated PRAMEF1 data layer compared with 4 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PRAMEF1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF1 expression acts as an unfavorable survival marker, although some lineages such as ESCA and SKCM show a favorable association.

KIRC, CHOL, and HNSC are the cancer types where PRAMEF1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	All	0.175	0.647	<.001	54	view →
CHOL	DFS	Tertile	All	0.086	0.510	<.001	45	view →
HNSC	OS	Tertile	All	0.243	0.428	.010	42	view →
ESCA	OS	Tertile	II,III,IV	0.936	0.655	.004	36	view →
BLCA	OS	Tertile	IV	0.368	0.613	.044	9	view →
OV	OS	Quartile	IV	0.428	0.659	.020	4	view →
SKCM	OS	Tertile	All	0.868	0.768	.021	3	view →
KIRP	DFS	Tertile	All	0.337	0.640	.045	3	view →
LIHC	DFS	Tertile	All	0.736	0.494	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PRAMEF1–KIRC (DFS)

Open the KIRC breakdown →